Journal article
Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
MD Cappellini, J Porter, A El-Beshlawy, CK Li, JF Seymour, M Elalfy, N Gattermann, S Giraudier, JW Lee, LL Chan, KH Lin, C Rose, A Taher, SL Thein, V Viprakasit, D Habr, G Domokos, B Roubert, A Kattamis
Haematologica | FERRATA STORTI FOUNDATION | Published : 2010
Abstract
Background: Following a clinical evaluation of deferasirox (Exjade®) it was concluded that, in addition to baseline body iron burden, ongoing transfusional iron intake should be considered when selecting doses. The 1-year EPIC study, the largest ever investigation conducted for an iron chelator, is the first to evaluate whether fixed starting doses of deferasirox, based on transfusional iron intake, with dose titration guided by serum ferritin trends and safety markers, provides clinically acceptable chelation in patients (aged ≥2 years) with transfusional hemosiderosis from various types of anemia. Design and Methods: The recommended initial dose was 20 mg/kg/day for patients receiving 2-4 ..
View full abstractGrants
Funding Acknowledgements
Funding: this study was sponsored by Novartis Pharma AG. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals.